ES8505820A1 - Un procedimiento para producir una vacuna que previene la infeccion de hepatitis b - Google Patents

Un procedimiento para producir una vacuna que previene la infeccion de hepatitis b

Info

Publication number
ES8505820A1
ES8505820A1 ES527588A ES527588A ES8505820A1 ES 8505820 A1 ES8505820 A1 ES 8505820A1 ES 527588 A ES527588 A ES 527588A ES 527588 A ES527588 A ES 527588A ES 8505820 A1 ES8505820 A1 ES 8505820A1
Authority
ES
Spain
Prior art keywords
hepatitis
producing
infection
causing
fractionation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES527588A
Other languages
English (en)
Other versions
ES527588A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Green Cross Corp Japan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp Japan filed Critical Green Cross Corp Japan
Publication of ES8505820A1 publication Critical patent/ES8505820A1/es
Publication of ES527588A0 publication Critical patent/ES527588A0/es
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

PROCEDIMIENTO PARA PRODUCIR UNA VACUNA QUE PREVIENE LA INFECCION DE HEPATITIS B.COMPRENDE: A) CALENTAR UNA SOLUCION ACUOSA DE UNA FRACCION DE PROTEINAS DELPLASMA HUMANO QUE CONTIENE ANTIGENO SUPERFICIAL DE HEPATITIS B, A UNA TEMPERATURA ENTRE 50 Y 70JC, DURANTE 8 A 12 HORAS; B) SATURAR A LA SOLUCION CALENTADA DE LA ETAPA (A) CON SULFATO DE AMONIO, PARA SEPARAR UNA FRACCION DE PROTEINAS PRECIPITABLES AL 10-20 Y RECOGER UNA FRACCION DE PROTEINAS PRECIPITABLES AL 40-50; C) PONER EN CONTACTO A LA SOLUCION AL 40-58 CON UN SILICATO COLOIDAL, PARA OBTENER HBSAG ABSORBIDO; D) ELUIR UNA PORCION DE HBSAG ABSORBIDO CON UNA SOLUCION TAMPON A PH ENTRE 8,5 Y 9; E) NEUTRALIZAR AL ELUATO DE LA ETAPA (D); F) AN/ADIR AL ELUATO, POLIETILENGLICOL HASTA UN NIVEL DE 3 A 7 (P/V) PARA SEPARAR VIRUS DE HEPATITIS B Y COMPLEJOS INMUNOLOGICOS; G) CONTINUAR AN/ADIENDO POLIETILENGLICOL HASTA OBTENER UN PRECIPITADO EN LA CAPA SOBRENADANTE DE (15-20) (P/V); H) FILTRAR AL PRECIPITADO PARA RECUPERAR UNA FRACCION DE HBSAG; I) ULTRACENTRIFUGAR A LA FRACCION DE LA ETAPA (H); J) INACTIVAR A LA FRACCION DE LA ETAPA (I) CON FORMALINA, Y K) REPOSAR AL PRODUCTO RESULTANTE.
ES527588A 1982-11-29 1983-11-28 Un procedimiento para producir una vacuna que previene la infeccion de hepatitis b Granted ES527588A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP57210240A JPS59101426A (ja) 1982-11-29 1982-11-29 Ｂ型肝炎感染予防用ワクチンの製造方法

Publications (2)

Publication Number Publication Date
ES8505820A1 true ES8505820A1 (es) 1985-06-16
ES527588A0 ES527588A0 (es) 1985-06-16

Family

ID=16586097

Family Applications (1)

Application Number Title Priority Date Filing Date
ES527588A Granted ES527588A0 (es) 1982-11-29 1983-11-28 Un procedimiento para producir una vacuna que previene la infeccion de hepatitis b

Country Status (6)

Country Link
US (1) US4565697A (es)
EP (1) EP0112506B1 (es)
JP (1) JPS59101426A (es)
CA (1) CA1217138A (es)
DE (1) DE3377972D1 (es)
ES (1) ES527588A0 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60193925A (ja) * 1984-03-13 1985-10-02 Chemo Sero Therapeut Res Inst 凍結乾燥製剤化ワクチン
US4695454A (en) * 1985-04-01 1987-09-22 New York Blood Center, Inc. Process for preparing hepatitis B surface antigen containing particles in novel forms which are highly immunogenic
US4683294A (en) * 1985-04-03 1987-07-28 Smith Kline Rit, S.A. Process for the extraction and purification of proteins from culture media producing them
US4649192A (en) * 1985-05-30 1987-03-10 Smith Kline-Rit Method for the isolation and purification of hepatitis B surface antigen using polysorbate
JPH0780785B2 (ja) * 1985-07-19 1995-08-30 株式会社ミドリ十字 Ｂ型肝炎ワクチンの製造方法
JPH0789951B2 (ja) * 1986-06-18 1995-10-04 財団法人阪大微生物病研究会 遺伝子発現産物の精製法
RU1389060C (ru) * 1986-08-13 1993-06-30 Институт иммунологии Способ получени рекомбинатной вакцины к гепатиту В
US4883865A (en) * 1987-09-30 1989-11-28 Merck & Co. Inc. Recovery of pres2+s antigen
CU22290A1 (es) * 1990-10-08 1995-01-31 Cigb Procedimiento para la obtencion de antigeno de superficie del virus de la hepatitis b de superior capacidad inmunoganica y su uso en un preparado vacunal
US5102989A (en) * 1991-03-15 1992-04-07 Merck & Co., Inc. Method of stabilizing recombinant hepatitis B virus surface proteins from recombinant host cells
US5709995A (en) * 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
US5543129A (en) * 1994-11-17 1996-08-06 Mg Industries Non-cryogenic method and apparatus for producing pure nitrogen
CN109134620A (zh) * 2018-09-21 2019-01-04 中国科学院过程工程研究所 一种纯化HBc-VLPs或HBc-VLPs衍生物的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3100737A (en) * 1958-02-05 1963-08-13 Auerswald Wilhelm Method of preparing a plasma protein solution free of active hepatitis virus and product produced thereby
US3636191A (en) * 1969-10-08 1972-01-18 Cancer Res Inst Vaccine against viral hepatitis and process
US3951937A (en) * 1973-12-20 1976-04-20 The Community Blood Council Of Greater New York, Inc. Large scale purification of hepatitis type B antigen using polyethylene glycol
US3994870A (en) * 1974-01-31 1976-11-30 The Community Blood Council Of Greater New York, Inc. Purification of hepatitis B surface antigen
JPS5417002B2 (es) * 1974-02-18 1979-06-27
DE2611723C3 (de) * 1976-03-19 1978-09-21 The Green Cross Corp., Osaka (Japan) Verfahren zur Herstellung von einheitlichen kugelförmigen HBsAg-Teilchen
US4057628A (en) * 1976-04-19 1977-11-08 William L. Wilson Removal of hepatitis associated antigen from plasma
JPS5840930B2 (ja) * 1976-09-20 1983-09-08 株式会社ミドリ十字 Ｂ型肝炎ワクチンの製造方法
US4162192A (en) * 1978-09-28 1979-07-24 Juridical Foundation Method for purification of HBs antigen
JPS5610119A (en) * 1979-07-05 1981-02-02 Alpha Therapeutic Corp Manufacture of b type hepatitis infection preventive vaccine
FR2470795A1 (fr) * 1979-12-07 1981-06-12 Pasteur Institut Procede de purification de particules d'origine biologique, notamment de l'antigene de surface du virus de l'hepatite b (aghbs) et les produits obtenus
US4349539A (en) * 1980-08-15 1982-09-14 Merck & Co., Inc. Separation of hepatitis B surface antigen
US4314997A (en) * 1980-10-06 1982-02-09 Edward Shanbrom Purification of plasma protein products
DE3043857A1 (de) * 1980-11-21 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ii und vii

Also Published As

Publication number Publication date
EP0112506A3 (en) 1985-05-22
JPH0585526B2 (es) 1993-12-07
DE3377972D1 (en) 1988-10-20
EP0112506B1 (en) 1988-09-14
ES527588A0 (es) 1985-06-16
CA1217138A (en) 1987-01-27
US4565697A (en) 1986-01-21
JPS59101426A (ja) 1984-06-12
EP0112506A2 (en) 1984-07-04

Similar Documents

Publication Publication Date Title
ES8505820A1 (es) Un procedimiento para producir una vacuna que previene la infeccion de hepatitis b
DK210283D0 (da) Fremgangsmade til fremstilling af plasma, plasmapraeparat og vaccine mod hepatitis
AU3216695A (en) Lipid analogs for treating viral infections
DK0835930T3 (da) Europæiske vaccinestammer af porcint reproduktions- og respirationssyndrom-virus. (PRRSV)
DE3268361D1 (en) New vaccine and therapy against non-a non-b viral hepatitis, and their preparation process
MY113428A (en) Hepatitis b vaccine
DE3680130D1 (de) Verfahren zur vireninaktivierung in gamma-globulin durch waermebehandlung.
PT88178A (pt) Metodo para a purificacao de virus da hepatite a
CA2197683A1 (en) Method for preparing an influenza virus, antigens obtained and applications thereof
AU580059B2 (en) Vaccine against rabies and preparation process thereof
NL300400I1 (en) Method and manufacture of an acellular vaccine comprising Bordetella pertussis antigens
EP0128522A3 (en) High titer cytomegalovirus immune serum globulin and method of making same
HU9300686D0 (en) Method for preparing vaccine preparative applicable for treatment of hiv infection
DE69432929D1 (de) Behandlung eines durch helicobakter verursachten gastroduodenalen krankheit
AU626684B2 (en) Mouse monoglonal antibodies for post-exposure treatment of rabies
DK0525502T4 (da) Fremgangsmåde til fremstilling af virusinaktiverede immunoglobulinoplösninger
EP1057889A4 (en) IMPROVED IMMUNOGEN FOR AN INACTIVE VACCINE AGAINST JAPANESE ENCEPHALITIS VIRUS INFECTION AND METHOD FOR THE PRODUCTION THEREOF
EP0234405A3 (en) Process for the preparation of an immunoglobulin-containing composition, and its use in the prophylaxis and therapy of aids
ATE179428T1 (de) Verfahren zur herstellung von hepatitis antigenen und impfstoffen
EP0090660A3 (en) Neisseria gonorrhoeae vaccine
EP0441395A3 (en) Human monoclonal antibody and pharmaceutical composition containing the same for the treatment of pseudomonas infections
AU3876793A (en) Process for the inactivation of viruses in preparations of proteins
PT75031B (en) Process for preparing pure hepatitis b surface antigen from human plasma
GR3021983T3 (en) Cross-reactive influenza a immunization
AU627540B2 (en) Drug for the treatment or prevention by passive immunization, of the hiv-infection and process for preparation thereof

Legal Events

Date Code Title Description
MM4A Patent lapsed

Effective date: 19960506